Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?
Fiche publication
Date publication
septembre 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOUVIER Anne-Marie, Pr GHIRINGHELLI François, Dr JOOSTE Valérie, Pr LEPAGE Côme
Tous les auteurs :
Mitry E, Rollot F, Jooste V, Guiu B, Lepage C, Ghiringhelli F, Faivre J, Bouvier AM
Lien Pubmed
Résumé
AIM OF THE STUDY: To describe trends in survival of non-resectable metastatic colorectal cancer (MCRC) over a 34-year period in a French population-based registry taking into account major advances in medical therapy. PATIENTS AND METHODS: 3804 patients with non-resectable metastatic colorectal cancer diagnosed between 1976 and 2009 were included. Three periods (1976-96, 1997-2004 and 2005-09) were considered. RESULTS: The proportion of patients receiving chemotherapy dramatically increased from 19% to 57% between the first two periods, then increased steadily thereafter reaching 59% during the last period (p
Référence
Eur J Cancer. 2013 Sep;49(13):2919-25